http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111417624-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-52 |
| filingDate | 2018-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111417624-B |
| titleOfInvention | Crystal form of EB-1020 and its preparation method and use |
| abstract | The present invention relates to a crystal form of compound (I) and a preparation method thereof, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of serotonin, norepinephrine and dopamine triple reuptake inhibitors and/or the treatment of nerve cells Use in pharmaceutical preparations for systemic disorders. The crystalline form of compound (I) provided by the present invention has one or more improved properties compared with the prior art, and is of great value to the optimization and development of the drug in the future. |
| priorityDate | 2017-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.